Literature DB >> 18460017

Depressed activation of the lectin pathway of complement in hereditary angioedema.

L Varga1, G Széplaki, J Laki, A Kocsis, K Kristóf, P Gál, Z Bajtay, J Wieslander, M R Daha, P Garred, H O Madsen, G Füst, H Farkas.   

Abstract

The possibility of simultaneous measurement of the classical pathway (CP), mannan-binding lectin (MBL)--lectin pathway (LP) and alternative pathway (AP) of complement activation by the recently developed Wielisa method allowed us to investigate the in vivo significance of the C1-inhibitor (C1INH) in three complement activation pathways. Functional activity of the CP, LP and AP were measured in the sera of 68 adult patients with hereditary angioedema (HAE) and 64 healthy controls. In addition, the level of C1q, MBL, MBL-associated serine protease-2 (MASP-2), C4-, C3- and C1INH was measured by standard laboratory methods. MBL-2 genotypes were determined by polymerase chain reaction. Besides the complement alterations (low CP and C1INH activity, low C4-, C1INH concentrations), which characterize HAE, the level of MASP-2 was also lower (P = 0.0001) in patients compared with controls. Depressed LP activity was found in patients compared with controls (P = 0.0008) in homozygous carriers of the normal MBL genotype (A/A), but not in carriers of variant genotypes (A/O, O/O). Activity of CP correlated with LP in patients (Spearman's r = 0.64; P < 0.0001), but no significant correlation was found in the control group and no correlation with AP was observed. In contrast, the activity of CP and AP correlated (Spearman's r = 0.47; P < 0.0001) in healthy controls, but there was no significant correlation in the HAE patients. We conclude that the activation of LP might also occur in subjects with C1INH deficiency, which is reflected by the low MASP-2 and C4 levels.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18460017      PMCID: PMC2432099          DOI: 10.1111/j.1365-2249.2008.03671.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  32 in total

1.  C1 inhibitor serpin domain structure reveals the likely mechanism of heparin potentiation and conformational disease.

Authors:  László Beinrohr; Veronika Harmat; József Dobó; Zsolt Lörincz; Péter Gál; Péter Závodszky
Journal:  J Biol Chem       Date:  2007-05-08       Impact factor: 5.157

2.  C4-binding protein prevents spontaneous cleavage of C3 in sera of patients with hereditary angioedema.

Authors:  P Gronski; L Bodenbender; E J Kanzy; F R Seiler
Journal:  Complement       Date:  1988

3.  Cooperation between MASP-1 and MASP-2 in the generation of C3 convertase through the MBL pathway.

Authors:  Mette Møller-Kristensen; Steffen Thiel; Anders Sjöholm; Misao Matsushita; Jens C Jensenius
Journal:  Int Immunol       Date:  2006-12-20       Impact factor: 4.823

4.  Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA.

Authors:  M A Seelen; A Roos; J Wieslander; T E Mollnes; A G Sjöholm; R Wurzner; M Loos; F Tedesco; R B Sim; P Garred; E Alexopoulos; M W Turner; M R Daha
Journal:  J Immunol Methods       Date:  2004-12-15       Impact factor: 2.303

5.  Protection from inflammatory disease in insulin resistance: the role of mannan-binding lectin.

Authors:  J M Fernández-Real; M Straczkowski; J Vendrell; F Soriguer; S Pérez Del Pulgar; L Gallart; A López-Bermejo; I Kowalska; M Manco; F Cardona; M M García-Gil; G Mingrone; C Richart; W Ricart; A Zorzano
Journal:  Diabetologia       Date:  2006-08-29       Impact factor: 10.122

Review 6.  Mannose-binding lectin: biology and clinical implications.

Authors:  D L Worthley; P G Bardy; C G Mullighan
Journal:  Intern Med J       Date:  2005-09       Impact factor: 2.048

7.  Heterogeneity of MBL-MASP complexes.

Authors:  Karine R Mayilyan; Julia S Presanis; James N Arnold; Krishnan Hajela; Robert B Sim
Journal:  Mol Immunol       Date:  2005-08-15       Impact factor: 4.407

8.  A hemolytic assay for the estimation of functional mannose-binding lectin levels in human serum.

Authors:  Saskia Kuipers; Piet C Aerts; Anders G Sjöholm; Theo Harmsen; Hans van Dijk
Journal:  J Immunol Methods       Date:  2002-10-15       Impact factor: 2.303

9.  Complement 1 inhibitor is a regulator of the alternative complement pathway.

Authors:  H Jiang; E Wagner; H Zhang; M M Frank
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307

Review 10.  Interactions between mannose-binding lectin and MASPs during complement activation by the lectin pathway.

Authors:  Russell Wallis
Journal:  Immunobiology       Date:  2006-12-18       Impact factor: 3.144

View more
  5 in total

1.  High levels of acute phase proteins and soluble 70 kDa heat shock proteins are independent and additive risk factors for mortality in colorectal cancer.

Authors:  Judit Kocsis; Tamás Mészáros; Balázs Madaras; Eva Katalin Tóth; Szilárd Kamondi; Péter Gál; Lilian Varga; Zoltán Prohászka; George Füst
Journal:  Cell Stress Chaperones       Date:  2010-08-22       Impact factor: 3.667

2.  Inputs for optimizing selection platform for milk production traits of dairy Sahiwal cattle.

Authors:  Destaw Worku; Gopal Gowane; Rani Alex; Pooja Joshi; Archana Verma
Journal:  PLoS One       Date:  2022-05-23       Impact factor: 3.752

Review 3.  "Nuts and Bolts" of Laboratory Evaluation of Angioedema.

Authors:  Henriette Farkas; Nóra Veszeli; Erika Kajdácsi; László Cervenak; Lilian Varga
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

4.  Cleavage of kininogen and subsequent bradykinin release by the complement component: mannose-binding lectin-associated serine protease (MASP)-1.

Authors:  József Dobó; Balázs Major; Katalin A Kékesi; István Szabó; Márton Megyeri; Krishnan Hajela; Gábor Juhász; Péter Závodszky; Péter Gál
Journal:  PLoS One       Date:  2011-05-23       Impact factor: 3.240

5.  The core genes involved in the promotion of depression in patients with ovarian cancer.

Authors:  Yuexiong Yi; Yanyan Liu; Kejia Wu; Wanrong Wu; Wei Zhang
Journal:  Oncol Lett       Date:  2019-09-30       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.